Post-marketing Registry of Inspiron Sirolimus Eluting Coronary Stent (Inspiron RL II)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03263260 |
Recruitment Status :
Active, not recruiting
First Posted : August 28, 2017
Last Update Posted : May 18, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Coronary Artery Disease | Device: implant |
Up to 5.0000 patients with native coronary arteries lesions with diameter between 2.5 and 4.0 mm and 34 mm of length treated solely with the Inspiron Sirolimus Eluting Coronary Stent.
Stent implantation should be performed according to the Instructions for Use and according to the local practice. It is recommended that ECG and cardiac enzymes are collected before and after procedure. Dual anti-platelet therapy is recommended for at least 6 months after procedure.
Patients will be followed at 30 days, 1 and 2 years after procedure.
Study Type : | Observational [Patient Registry] |
Estimated Enrollment : | 5000 participants |
Observational Model: | Other |
Time Perspective: | Prospective |
Target Follow-Up Duration: | 24 Months |
Official Title: | Prospective, Multicentric, Post-marketing Registry of Inspiron Sirolimus Eluting Coronary Stent for Treatment of Patients With Native Coronary Artery Lesions (Inspiron Real Life II) |
Actual Study Start Date : | June 2, 2017 |
Actual Primary Completion Date : | December 15, 2022 |
Estimated Study Completion Date : | December 30, 2023 |

Group/Cohort | Intervention/treatment |
---|---|
implanted patients
Patients with native coronary artery lesions with diameter between 2.5 and 4.0 and 34 mm of length treated only with the Inspiron Sirolimus eluting Stent
|
Device: implant
coronary stent implantation |
- Major Adverse Cardiac Events Rate [ Time Frame: 12 months ]Cardiac Death, MI, Target Lesion Revascularization and Stent Thrombosis
- Target Vessel and Lesion Revascularization Rates [ Time Frame: 24 months ]Target Vessel and Lesion Revascularization
- Stent Thrombosis Rate [ Time Frame: 24 months ]Stent Thrombosis

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- alll patients that have been treated with the Inspiron Sirolimus Eluting Stent older and 18 years
Exclusion Criteria:
- Safein Vein or Left Internal Mammary artery Grafts

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03263260
Brazil | |
União Brasileira de Educação e Assistência - Hospital São Lucas da PUC - RS | |
Porto Alegre, Rio Grande Do Sul, Brazil, 90.619-900 |
Responsible Party: | Scitech Produtos Medicos Ltda |
ClinicalTrials.gov Identifier: | NCT03263260 |
Other Study ID Numbers: |
Inspiron RL II |
First Posted: | August 28, 2017 Key Record Dates |
Last Update Posted: | May 18, 2023 |
Last Verified: | April 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
stent, DES, Inspiron |
Coronary Artery Disease Coronary Disease Myocardial Ischemia Heart Diseases |
Cardiovascular Diseases Arteriosclerosis Arterial Occlusive Diseases Vascular Diseases |